Real‐world incidence and risk factors of level 3 (severe) hypoglycaemia in adults with type 1 or 2 diabetes ( iNPHORM , United States)
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Alexandria Ratzki-Leewing und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Maryland Institute for Health Computing, North Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Hypoglycemia, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi Global, Montgomery County, Maryland and The University of Maryland Strategic Partnership: MPowering the State, NIDDK NIH HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Level 3 (severe) hypoglycaemia is a serious, yet preventable, complication of insulin‐ or secretagogue‐treated diabetes. However, real‐world insight into its incidence and risk factors remains limited. We analysed data from the iNPHORM study to address this gap. Materials and Methods iNPHORM is a prospective internet panel survey of US adults (aged 18–90) with type 1 diabetes (T1D) or insulin‐ and/or secretagogue‐treated type 2 diabetes (T2D). A screener, baseline and 12‐monthly follow‐up questionnaires captured data on Level 3 hypoglycaemia and participant characteristics. Crude incidence proportions and annualized event rates were calculated. Repeated LASSO selection and negative binomial regression identified risk factors, with separate models for T1D and T2D.
Results
Among 985 participants (T1D: 16.7%), 35.0% experienced ≥1 Level 3 event over follow‐up (T1D: 45.0%; T2D: 33.0%). The annualized rate was 4.98 EPPY (T1D: 3.56; T2D: 5.26). In T1D, rates were higher among individuals identifying as non‐White (RR [rate ratio]: 2.03), with prior diabetes ketoacidosis (RR: 6.49), and greater fear of hypoglycaemia (RR: 1.41). Prior diabetes education (RR: 0.42) was protective. In T2D, rates were higher with younger age (RR: 0.77 per 10‐year increase), greater fear of hypoglycaemia (RR: 1.18), more diabetes complications, higher secretagogue dose, more diabetes visits (RR: 1.72), longer use of continuous/flash glucose monitoring, impaired awareness of hypoglycaemia and a greater number of past healthcare‐requiring severe hypoglycaemia (RR: 1.12).
Conclusions
Level 3 hypoglycaemia remains common in T1D and T2D. Findings support risk‐targeted prevention and diabetes care strategies that co‐prioritize safety and effectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Maryland Institute for Health Computing, North Bethesda, Maryland, USA.
- Division of Gerontology, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
- Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western Centre for Public Health and Family Medicine, Western University, London, Ontario, Canada.
- Department of Family Medicine, Schulich School of Medicine & Dentistry, Western Centre for Public Health and Family Medicine, Western University, London, Ontario, Canada.
- Robarts Research Institute, Western University, London, Ontario, Canada.
- Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
ORCID-Profile: Alexandria Ratzki-Leewing, Yu Kuei Lin
Förderung
- Sanofi Global
- Montgomery County, Maryland and The University of Maryland Strategic Partnership: MPowering the State
- NIDDK NIH HHS
- Montgomery County Government
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Ratzki-Leewing, A., Black, J. E., Bhatti, J., Ryan, B. L., Zou, G., Lin, Y. K., Huang, S. J., McCoy, R. G., & Harris, S. B. (2026). Real‐world incidence and risk factors of level 3 (severe) hypoglycaemia in adults with type 1 or 2 diabetes ( iNPHORM , United States). Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70252
Vancouver
Ratzki-Leewing A, Black JE, Bhatti J, Ryan BL, Zou G, Lin YK, et al. Real‐world incidence and risk factors of level 3 (severe) hypoglycaemia in adults with type 1 or 2 diabetes ( iNPHORM , United States). Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70252
BibTeX
@article{RatzkiLeewing2026,
author = {Ratzki-Leewing, Alexandria and Black, Jason E and Bhatti, Jasminder and Ryan, Bridget L and Zou, Guangyong and Lin, Yu Kuei and Huang, Shuo J and McCoy, Rozalina G and Harris, Stewart B},
title = {Real‐world incidence and risk factors of level 3 (severe) hypoglycaemia in adults with type 1 or 2 diabetes ( iNPHORM , United States)},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70252}
}
EUVIMED